HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.

Gregory D HuhnMoti RamgopalMamta K JainFederico HinestrosaDavid M AsmuthJihad SlimDeborah GoldsteinShauna ApplinJulie H RyuShuping JiangStephanie CoxMoupali DasThai Nguyen-ClearyDavid PiontkowskyBill GuyerLorenzo RossaroRichard H Haubrich

Published in: PloS one (2020)

This study supports LDV/SOF co-administered with an F/TAF-based regimen in HIV-1/HCV-GT1 co-infected patients.

Keyphrases

hepatitis c virus
human immunodeficiency virus
antiretroviral therapy
hiv infected
hiv positive
hiv testing
hiv aids
open label
randomized controlled trial
stem cells
phase ii
bone marrow
study protocol